Journal of Hepatology
Publisher: Elsevier · ISSN 0168-8278 · 80 articles
- Get ready for EASL Congress 2027 and submit your abstract by 19 January!
- Register for the EASL Liver Cancer Summit 2027! 14-16 January, Valencia (Spain)
- Register for the EASL Steatotic Liver Disease Summit 2027! 10-13 February, Berlin (Germany)
- The LIVERAIM project aims to create and validate a biomarker-based screening platform to enable early detection of liver disease in asymptomatic individuals
- Contents
- From the Editor’s desk...
- JHEP at a glance (November 2026)
- From evidence to action: The WHO–Imperial–EASL Collaborating Centre on Steatotic Liver Disease
- MASLD, MASH, and MARCHF6: Introducing a new player in fatty liver disease
- IL-19 limits macrophage-driven inflammation in acetaminophen-induced liver injury
- Decoding primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma: The myeloid frontier
- Beyond editing: Delivery systems will shape the future of gene therapy for chronic liver disease
- Unveiling the biology of liver fibrosis: A miniseries on the mechanisms, diagnostics, and reversibility of liver fibrosis
- MARCHF6 orchestrates hepatic lipid homeostasis by targeting SREBP1 for ER-associated degradation
- HbA1c trajectories and the risk of liver-related events in patients with type 2 diabetes mellitus
- Dysregulated transcription in core- and pol-specific CD8 T cells can be targeted by HDAC inhibition to improve T-cell function in chronic hepatitis B
- Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
- Anserine restores antibacterial immunity in cirrhosis via protective CCL5-mediated hepatocyte-CD44+ pDC crosstalk
- A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
- MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
- Anti-CCL2-conjugated platelets attenuate early allograft and ischemia–reperfusion injury by inhibiting monocyte infiltration
- In vivo base editing alleviates hepatic iron accumulation and fibrosis in models of HFE-related hereditary hemochromatosis
- Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease
- The hepato-exposome axis: How endocrine disruptors hijack liver receptors to drive MASLD
- Baveno VIII – Advancing consensus in portal hypertension
- Regression of liver cirrhosis
- Fibrosis regression in chronic liver disease: The pathologist’s view
- From prevalence to programme: Liver fibrosis screening after LiverScreen
- Advancing functional cure for hepatitis B virus infection
- Mitochondrial NAD+ determines the metabolic capacity for liver regeneration